Method for preparing soluble guanylate cyclase stimulator
By reacting the amidine compound with a specific compound in the presence of a base, the 3-substituted 1,2,4-triazole compound was prepared, which solved the problems of preparation efficiency and purity of sGC stimulators in the prior art, and achieved high yield and high purity mass manufacturing avoids the use of harmful substances.
Patent Information
- Application Number
- CN201980017653.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-03-07
- Filing Date
- 2019-03-07
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2039-03-07
AI Technical Summary
The prior art is difficult to efficiently prepare high-yield, high-purity soluble guanylate cyclase (sGC) stimulators with high yield and high purity, and often use harmful hydrazine as reagents, which limits its wide application.
3-substituted 1,2,4-triazole compounds are prepared by reacting the amidine compound with a carboxylic acid, activated ester, thioester, acid halide, thioacyl halide or acid anhydride in the presence of a base, avoiding chromatographic purification and use harmful hydrazine, suitable for large-scale manufacturing.
The preparation of sGC stimulators with high yield and high purity is achieved, which simplifies the process, is suitable for large-scale production, and avoids the use of harmful substances.
Smart Images

Figure BDA0002669218250000021 
Figure BDA0002669218250000022 
Figure BDA0002669218250000051
Abstract
Description
[0001]
Related applications
[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 639,642, filed on March 7, 2018, under 35 U.S.C. §119(e), the entire contents of which are incorporated herein by reference. [Technical field]
[0003] The present invention relates to a novel method for preparing a soluble guanylate cyclase (sGC) stimulator.
[0004] [Prior Art]
[0005] Compounds that stimulate soluble guanylate cyclase (sGC) are useful for treating a variety of diseases and conditions in which concentrations of nitric oxide (NO) or cyclic guanosine 3',5'-monophosphate (cGMP) or both are elevated, or in which upregulation of the NO pathway is desired. Such diseases and conditions include, but are not limited to, pulmonary hypertension, arterial hypertension, heart failure, atherosclerosis, inflammation, thrombosis, renal fibrosis and failure, cirrhosis, erectile dysfunction, female sexual dysfunction, conditions associated with diabetes, ocular disorders, and other related cardiovascular disorders. sGC stimulators offer considerable advantages over other current alternative therapies that target an aberrant NO pathway or combat diseases in which upregulation of the NO pathway is beneficial.
[0006] sGC stimulators are disclosed in U.S. Application Serial No. 15 / 693,758, the entire teachings of which are incorporated herein by reference. Successful commercialization of new therapeutic agents requires efficient methods for preparing the therapeutic agents in high yield and high purity. Therefore, there remains a need for improved methods for preparing sGC stimulators that are more efficient and suitable for large-scale processing. [Summary of the invention]
[0007] The present invention provides a variety of methods for preparing 3-substituted 1,2,4-triazole compounds as sGC stimulators and their synthetic precursors. Compared with previously disclosed methods, the methods of the present invention can produce sGC stimulators in higher yields and high purity. In particular, the methods of the present invention can produce sGC stimulators via a shortened, more practical and higher yielding synthetic process that provides the final product in much higher purity while eliminating all chromatographic purification and the use of harmful hydrazines as reagents (thus more suitable for large-scale manufacturing). These methods are more suitable for large-scale processes.
[0008] In a first aspect, disclosed herein is a method for preparing a 3-substituted 1,2,4-triazole compound, comprising reacting an amidrazone compound with a carboxylic acid, an activated ester, a thioester, an acyl halide, a thioacyl halide, or an anhydride in the presence of a base. When a carboxylic acid is used, an activating agent is also present. The amidrazone compound comprises an amidrazone bonded to an optionally substituted aryl or heteroaryl group; the substituent at the 3-position of the 3-substituted 1,2,4-triazole compound is an optionally substituted aryl or heteroaryl group bonded to the amidrazone compound; and the 3-substituted 1,2,4-triazole compound may be optionally substituted at the 5-position.
[0009] The method of the present invention can be preferably used to prepare the 3-substituted 1,2,4-triazole compound disclosed in U.S. Application Serial No. 15 / 693,758. Specifically, the first embodiment of the first aspect is a method for preparing a 3-substituted 1,2,4-triazole compound represented by the following formula IA:
[0010]
[0011] or a salt thereof. The method comprises reacting a guanylhydrazone compound represented by the following formula IIA in the presence of a base:
[0012]
[0013] or its salts with R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X′、R 11 C(O)OE′、R 11 C(O)SR′ or R 11 C(O)OR" reaction, in which when R 11 C(O)OH, an activator is also present. Formula IA, Formula IIA, R 11 C(O)OH、R 11 C(O)X′、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR' and R 11 The values of the variables in "C(O)OR" are defined as follows:
[0014] Ring E and Ring A form a molecular core and are aromatic; X and Y are each independently selected from N, NR n and C; at most 4 of X and Y are both N and R n H or C 1-6 alkyl;
[0015] W
[0016] i) does not exist, where J Bdirectly attached to a carbon atom carrying two J groups, each J being independently hydrogen or methyl, n being 1 and J B is C optionally substituted with up to 9 fluorine groups 1-7 an alkyl chain; or
[0017] ii) is ring B, which is phenyl, C 3-7 a cycloalkyl ring or a 5- or 6-membered heteroaryl ring containing 1 or 2 ring nitrogen atoms;
[0018] wherein when ring B is phenyl or a 5-membered or 6-membered heteroaryl ring; each J is independently hydrogen or methyl; n is an integer selected from 0 to 3; and each J B are independently selected from halo, -CN, C 1-6 Aliphatic, -OR B and C 3-8 alicyclic rings; and
[0019] When ring B is C 3-7 When the ring is a cycloalkyl ring; each J is hydrogen; n is an integer selected from 0 to 3 and each J B are independently selected from halo, -CN, C 1-6 Aliphatic and -OR B1 ;
[0020] Among them is C 1-6 Aliphatic J B and C 3-8 The J of the alicyclic ring B Optionally and independently through up to 3 R 3 replace;
[0021] Each R B Independently for C 1-6 Aliphatic or C 3-8 alicyclic ring; said R B Optionally and independently through up to 3 R 3a replace;
[0022] Each R B1 are independently selected from hydrogen, C 1-6 Aliphatic and C 3-8 alicyclic ring; wherein the C 1-6 Each of the aliphatic groups and the C 3-8 Each of the alicyclic rings is optionally and independently substituted with up to 3 R 3b replace;
[0023] In each case, each R 3 , R 3a and R 3b are independently selected from halo, -CN, C 1-4 Alkyl, C 1-4 Haloalkyl, -O(C 1-4 Alkyl) and -O(C1-4 haloalkyl);
[0024] p is an integer selected from 1, 2 and 3;
[0025] Each J C are independently selected from hydrogen, halogen, C 1-4 Aliphatic, C 1-4 Alkoxy and -CN; wherein each of the C 1-4 Aliphatic and C 1-4 Alkoxy optionally and independently has up to 3 C 1-4 Alkoxy, C 1-4 Haloalkoxy, -OH or halogen substitution;
[0026] R 11 H; -NR a2 R b2 ;-C(O)NR a2 R b2 ;-C(O)R 15a ; -CN; optionally and independently 0 to 2 R b2 Substituted C 2-6 optionally and independently 0 to 2 R b2 Substituted C 2-6 Alkynyl; optionally and independently 0 to 3 R 15 Substituted C 1-6 Alkyl; optionally and independently 0 to 5 R 15 Substituted C 1-6 Alkoxy; optionally and independently 0 to 3 R 15 substituted phenyl; optionally and independently substituted with 0 to 3 R 15 substituted 5- to 6-membered heteroaryl; optionally and independently substituted with 0 to 3 R 15 Substituted C 3-8 Cycloalkyl or optionally and independently substituted with 0 to 3 R 15 substituted 3- to 8-membered heterocyclyl; wherein each of the 5- to 6-membered heteroaryl and each of the 3- to 8-membered heterocyclyl contains up to 3 ring heteroatoms independently selected from N, O and S;
[0027] R 15 is a halogen group; -OR b2 ;-SR b2 ;-NR a2 R b2 ;-C(O)R b2 ;-C(O)NR a2 R b2 ;-NR b2 C(O)OR b2 ;-OC(O)NR a2 R b2 ; C2-4 optionally and independently 0 to 3 R 18 Substituted C 3-8 Cycloalkyl; optionally and independently substituted with 0 to 3 R 18 substituted phenyl; optionally and independently substituted with 0 to 3 R 18 substituted 5-membered or 6-membered heteroaryl or optionally and independently substituted with 0 to 3 R 18 substituted 3- to 10-membered heterocyclyl; wherein each of the 5- or 6-membered heteroaryl rings and each of the 3- to 10-membered heterocyclyl contains up to 3 ring heteroatoms independently selected from N, O and S;
[0028] R 15a is optionally and independently 0 to 3 R 18 Substituted C 3-8 Cycloalkyl; optionally and independently substituted with 0 to 3 R 18 substituted phenyl; optionally and independently substituted with 0 to 3 R 18 substituted 5-membered or 6-membered heteroaryl or optionally and independently substituted with 0 to 3 R 18 substituted 3- to 10-membered heterocyclyl; wherein each of the 5- or 6-membered heteroaryl rings and each of the 3- to 10-membered heterocyclyl contains up to 3 ring heteroatoms independently selected from N, O and S;
[0029] Each R 18 are independently selected from halo, hydroxy, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl and phenyl;
[0030] R a2 is hydrogen, -C(O)R b2 , C 1-6 Alkyl or C 1-6 Haloalkyl;
[0031] R b2 For hydrogen, C 1-6 Alkyl or C 1-6 Haloalkyl;
[0032] X′ is a halide;
[0033] OE′ is an activated ester leaving group;
[0034] SR' is a thioester leaving group;
[0035] R" is C(O)R 11 、C(O)R 11a 、N=CR 11b R 11c , P(O)(OH)2 or PH(O)OH;
[0036] R 11a C 1-6 alkyl;
[0037] R 11b and R 11c Each independently is C 1-6 Alkyl or phenyl, or R 11b and R 11c Together with the carbon atom to which it is attached, it forms C 4-6 Cycloalkyl; and
[0038] G 1 It is a guanylhydrazone protecting group.
[0039] In a second aspect, the present invention provides a synthetic intermediate for use in the method of the present invention. A first embodiment of the second aspect is a compound represented by the following formula IIA:
[0040]
[0041] or a salt thereof, wherein:
[0042] Ring E and Ring A form a molecular core and are aromatic; X and Y are each independently selected from N, NR n and C; at most 4 of X and Y are both N and R n H or C 1-6 alkyl;
[0043] W
[0044] i) does not exist, where J B directly attached to a carbon atom carrying two J groups, each J being independently hydrogen or methyl, n being 1 and J B is C optionally substituted with up to 9 fluorine groups 1-7 an alkyl chain; or
[0045] ii) is ring B, which is phenyl, C 3-7 a cycloalkyl ring or a 5- or 6-membered heteroaryl ring containing 1 or 2 ring nitrogen atoms;
[0046] wherein when ring B is phenyl or a 5-membered or 6-membered heteroaryl ring; each J is independently hydrogen or methyl; n is an integer selected from 0 to 3; and each J B are independently selected from halo, -CN, C 1-6 Aliphatic, -OR B and C 3-8 alicyclic rings; and
[0047] When ring B is C 3-7 When the ring is a cycloalkyl ring; each J is hydrogen; n is an integer selected from 0 to 3 and each J B are independently selected from halo, -CN, C 1-6Aliphatic and -OR B1 ;
[0048] Among them is C 1-6 Aliphatic J B and C 3-8 The J of the alicyclic ring B Optionally and independently through up to 3 R 3 replace;
[0049] Each R B Independently for C 1-6 Aliphatic or C 3-8 alicyclic ring; said R B Optionally and independently through up to 3 R 3a replace;
[0050] Each R B1 are independently selected from hydrogen, C 1-6 Aliphatic and C 3-8 alicyclic ring; wherein the C 1-6 Each of the aliphatic groups and the C 3-8 Each of the alicyclic rings is optionally and independently substituted with up to 3 R 3b replace;
[0051] In each case, each R 3 , R 3a and R 3b are independently selected from halo, -CN, C 1-4 Alkyl, C 1-4 Haloalkyl, -O(C 1-4 Alkyl) and -O(C 1-4 haloalkyl);
[0052] p is an integer selected from 1, 2 or 3;
[0053] Each J C are independently selected from hydrogen, halogen, C 1-4 Aliphatic, C 1-4 Alkoxy and -CN; wherein each of the C 1-4 Aliphatic and C 1-4 Alkoxy optionally and independently has up to 3 C 1-4 Alkoxy, C 1-4 Haloalkoxy, -OH or halo substituted; and
[0054] G 1 is a guanylhydrazone protecting group or a salt thereof.
[0055] [Implementation Method]
[0056] Reference will now be made in detail to certain embodiments of the present invention, examples of which are illustrated in the accompanying structures and formulas. Although the present invention will be described in conjunction with the enumerated embodiments, it should be understood that it is not intended to limit the present invention to those embodiments. On the contrary, the present invention is intended to cover all alternatives, modifications and equivalents that may be included within the scope of the present invention as defined by the scope of the claims. Those skilled in the art will recognize that a variety of methods and materials similar to or equivalent to the methods and materials described herein may be used in the practice of the present invention.
[0057] It should be understood that any of the embodiments described herein can be combined with one or more other embodiments of the present invention, unless explicitly denied or inappropriate. The combination of embodiments is not limited to those specific combinations claimed by the multiple subsidiary technical solutions.
[0058] definition
[0059] For purposes of the present invention, chemical elements are identified according to the Periodic Table of the Elements, CAS version, and Handbook of Chemistry and Physics, 75th Edition, 1994. In addition, general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999 and "March's Advanced Organic Chemistry", 5th Edition, Smith, MB and March, J. (Eds.), John Wiley & Sons, New York: 2001, the entire contents of which are incorporated herein by reference.
[0060] As described herein, compounds of Formula IA or Formula IIA may be optionally substituted with one or more substituents, such as those generally described below or exemplified by specific classes, subclasses, and species of the present invention. The phrase "optionally substituted" may be used interchangeably with the phrase "substituted or unsubstituted." In general, the term "substituted" refers to the replacement of one or more hydrogen radicals in a given structure with a group of a specified substituent. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group. Unless otherwise specified, when more than one position in a given structure may be substituted with more than one substituent selected from a specified group, the substituent may be the same or different at each position. The term "optionally and independently" may be used to describe this situation. As an example, a substituent disclosed herein is R 11 In other options, it can also be optionally and independently substituted with 0 to 3 R 15 Substituted C 1-6 In this case, C 1-6 An alkyl group may be "optionally substituted": it may be unsubstituted (ie, R 150 occurrences) or is replaced (i.e., R 15 appears 1, 2 or 3 times). When R 15 When it appears multiple times (for example, twice), each R 15 The substituents may be the same (e.g., two fluorine atoms) or different (e.g., -OH and chlorine). As will be apparent to one of ordinary skill in the art, groups such as -H, halogen, -NO2, -CN, -OH, -NH2, or -OCF3 are not substitutable groups.
[0061] As used herein, the phrase "at most" refers to zero or any integer value that is equal to or less than the value following the phrase. For example, "at most 3" means any one of 0, 1, 2, and 3. As described herein, a specified numerical range of atoms includes any integer therein. For example, a group having 1 to 4 atoms may have 1, 2, 3, or 4 atoms. A group having 0 to 3 atoms may have 0, 1, 2, or 3 atoms. When any variable occurs more than once at any position, its definition at each occurrence is independent of its definition at every other occurrence.
[0062] Compounds such as Formula IA or Formula IIA or other compounds disclosed herein may exist in their free form (e.g., amorphous form or crystalline form or polymorph). Under certain conditions, the compounds may also form co-formers. As used herein, the term co-former is synonymous with the term multi-component crystalline form. The formation of salts is determined by the difference in pK between the partners that form the mixture. For the purposes of the present invention, the compounds include pharmaceutically acceptable salts, even if the term "pharmaceutically acceptable salt" is not explicitly stated.
[0063] Unless only one of the isomers is specifically drawn or named, structures depicted herein are also intended to include all stereoisomeric (e.g., enantiomeric, diastereomeric, atropoisomeric, and cis-trans isomeric) forms of the structure; for example, R and S configurations for each asymmetric center, Ra and Sa configurations for each asymmetric axis, (Z) and (E) double bond configurations, and cis- and trans-configurational isomers. Therefore, single stereochemical isomers of the compounds of the invention as well as racemates and mixtures of enantiomers, diastereomers, and cis- and trans-isomers (double bond or configuration) are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are also within the scope of the invention.
[0064] The present invention also encompasses isotopically labeled compounds which are equivalent to those listed herein except that one or more atoms are replaced by an atom with an atomic mass or mass number different from the atomic mass or mass number usually found in nature. All isotopes of any particular atom or element as specified are encompassed within the scope of the present compounds and their uses. Exemplary isotopes that can be incorporated into the present compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 32 P. 33 P. 35 S. 18 F. 36 Cl, 123 I and 125 I. Certain isotopically labeled compounds of the present invention (e.g. 3 H or 14 C-labeled) are suitable for compound and / or substrate tissue distribution analysis. 3 H) and carbon-14 (i.e. 14 C) isotopes are useful because of their ease of preparation and detectability. Alternatively, deuterium (i.e., 2 Substitution of heavier isotopes with H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. 15 O. 13 N. 11 C and 18 Positron emitting isotopes of F are useful in positron emission tomography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the Schemes and / or in the Examples below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
[0065] As used herein, the term "aliphatic" or "aliphatic group" or "aliphatic chain" means a straight chain (i.e., non-branched chain) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or contains one or more unsaturated units. Unless otherwise specified, an aliphatic group contains 1 to 20 aliphatic carbon atoms. In some embodiments, an aliphatic group contains 1 to 10 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1 to 8 aliphatic carbon atoms. In yet other embodiments, an aliphatic group contains 1 to 6 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1 to 4 aliphatic carbon atoms, and in yet other embodiments, an aliphatic group contains 1 to 3 or 1 to 2 aliphatic carbon atoms. Suitable aliphatic groups include, but are not limited to, straight or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl. Specific examples of aliphatic groups include, but are not limited to, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, vinyl, sec-butyl, tert-butyl, butenyl, propargyl, acetylene, and the like. Aliphatic groups will be represented by the term "C x-y "Aliphatic" means; wherein x and y are the minimum and maximum number of carbon atoms forming the aliphatic chain.
[0066] As used herein, the term "alkyl" (as in "alkyl chain" or "alkyl group") refers to a saturated straight or branched monovalent hydrocarbon radical. Unless otherwise specified, an alkyl group contains 1 to 20 carbon atoms (e.g., 1 to 20 carbon atoms, 1 to 10 carbon atoms, 1 to 8 carbon atoms, 1 to 7 carbon atoms, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1 to 3 carbon atoms). Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl / sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, and the like. Alkyl groups will be represented by the term "C x-y "alkyl" means; wherein x and y are the minimum and maximum number of carbon atoms forming the alkyl chain.
[0067] The term "alkenyl" (as in "alkenyl chain" or "alkenyl group") refers to an alkenyl group having at least one site of unsaturation (ie, a carbon-carbon sp 2 A straight or branched monovalent hydrocarbon radical having a double bond (with a cyclopentyl group), wherein alkenyl includes radicals having "cis" and "trans" orientations or alternatively "E" and "Z" orientations. Unless otherwise specified, alkenyl contains 2 to 20 carbon atoms (e.g., 2 to 20 carbon atoms, 2 to 10 carbon atoms, 2 to 8 carbon atoms, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 to 3 carbon atoms). Examples include, but are not limited to, vinyl, allyl, and the like. Alkenyl groups will be represented by the term "C x-y "Alkenyl" means; wherein x and y are the minimum and maximum number of carbon atoms forming the alkenyl chain.
[0068] The term "alkynyl" (as in "alkynyl chain" or "alkynyl group") refers to a straight or branched monovalent hydrocarbon radical having at least one site of unsaturation (i.e., a carbon-carbon sp triple bond). Unless otherwise specified, an alkynyl group contains 2 to 20 carbon atoms (e.g., 2 to 20 carbon atoms, 2 to 10 carbon atoms, 2 to 8 carbon atoms, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 to 3 carbon atoms). Examples include, but are not limited to, ethynyl, propynyl, and the like. Alkynyl groups are represented by the term "C x-y "alkynyl" means; wherein x and y are the minimum and maximum number of carbon atoms forming the alkynyl chain.
[0069] The term "cycloaliphatic" (or "non-aromatic carbocycle", "non-aromatic carbocyclyl", "non-aromatic carbocyclic" or "alicyclic ring") refers to a cyclic hydrocarbon that is fully saturated or contains one or more unsaturated units but is not aromatic and has a single point of attachment to the rest of the molecule. In one embodiment, the term "cycloaliphatic" refers to a monocyclic C 3-8 Hydrocarbon or monocyclic C 3-12 Hydrocarbons. The alicyclic ring will be represented by the term "C x-y "Cycloaliphatic" means; wherein x and y are the minimum and maximum number of carbon atoms forming the alicyclic ring. Suitable cycloaliphatic groups include, but are not limited to, cycloalkyl, cycloalkenyl, and cycloalkynyl. Examples of cycloaliphatic groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, norbornyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, and the like.
[0070] As used herein, "cycloalkyl" or "cycloalkyl ring" refers to a ring system that is fully saturated and has a single point of attachment to the rest of the molecule. In one embodiment, the term "cycloalkyl" refers to a monocyclic C 3-12 For example, the term "cycloalkyl" refers to a monocyclic C 3-7 Saturated hydrocarbon or monocyclic C 3-8 Saturated hydrocarbons. Suitable cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, and the like. The cycloalkyl ring will be represented by the term "C x-y "Cycloalkyl" means wherein x and y are the minimum and maximum number of carbon atoms forming the cycloalkyl ring.
[0071] As used herein, "aryl" refers to a substituted or unsubstituted monocyclic aromatic group in which each atom of the ring is carbon. The ring is preferably a 5- to 7-membered ring, more preferably a 6-membered ring. Aryl groups include, but are not limited to, phenyl, phenol, aniline, and the like. The term "aryl" also includes "polycyclic", "polycyclic" and "polycyclic" ring systems having two or more rings, in which two or more atoms are shared by two adjacent rings (e.g., the ring is a "fused ring"), wherein at least one ring is aromatic, for example, the other cyclic rings may be cycloalkyl, cycloalkenyl, cycloalkynyl or aromatic rings. In some preferred embodiments, the polycyclic ring has 2 to 3 rings. In certain preferred embodiments, the polycyclic ring system has two cyclic rings, both of which are aromatic. Each of the polycyclic rings may be substituted or unsubstituted. In certain embodiments, each ring of the polycyclic ring contains 3 to 10, preferably 5 to 7 carbon atoms in the ring. For example, aryl groups include, but are not limited to, phenyl (benzene), tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, and naphthyl, as well as benzo-fused carbocyclic moieties such as 5,6,7,8-tetrahydronaphthyl, and the like. In some embodiments, aryl is a monocyclic aromatic group. In some embodiments, aryl is a bicyclic aromatic group. In some embodiments, aryl is a tricyclic aromatic group.
[0072] As used herein, "heterocycle" (or "heterocyclyl" or "heterocyclic" or "heterocyclic ring") refers to a ring system in which one or more ring members are independently selected heteroatoms, which is fully saturated or contains one or more unsaturated units but is not aromatic, and which has a single point of attachment to the rest of the molecule. Unless otherwise specified, heterocycle is used as a synonym for "non-aromatic heterocycle" throughout the present invention. In some instances, the term may be used in the phrase "aromatic heterocycle", and in this case it shall refer to a "heteroaryl group" as defined below. In some embodiments, the heterocycle has 3 to 8 ring members or 3 to 10 ring members, wherein one or more ring members are heteroatoms independently selected from nitrogen, oxygen, or sulfur. In other embodiments, the heterocycle may be a monocyclic ring having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 4 heteroatoms). For example, up to 3 ring heteroatoms are independently selected from nitrogen, oxygen, or sulfur.
[0073] Examples of heterocyclic rings include, but are not limited to, the following monocyclic rings: 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-(N-morpholinyl), 3-(N-morpholinyl), 4-(N-morpholinyl), 2-(N-thiomorpholinyl), 3-(N-thiomorpholinyl), 4-(N-thiomorpholinyl), 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-tetrahydropiperidin ... 4-Imidazolidinyl, 2-thiazolidinyl, 3-thiazolidinyl, 4-thiazolidinyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, and 5-imidazolidinyl.
[0074] The term "heteroaryl" (or "heteroaromatic" or "heteroaryl group" or "aromatic heterocycle" or "heteroaryl ring") used alone or as part of a larger moiety as in "heteroarylalkyl" or "heteroarylalkoxy" refers to a ring that is aromatic and contains one or more ring heteroatoms (e.g., one or two ring nitrogen atoms), has between 5 and 6 ring members and which has a single point of attachment to the rest of the molecule. Heteroaryl rings include, but are not limited to, the following monocyclic rings: 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g. 5-tetrazolyl), triazolyl (e.g. 2-triazolyl and 5-triazolyl), 2-thienyl, 3-thienyl, pyrazolyl (e.g. 2-pyrazolyl), isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, pyrazinyl, 1,3,5-triazinyl.
[0075] The term "ring atom" refers to an atom that is a ring part of an aromatic ring, alicyclic ring, heterocycle or heteroaryl ring, such as C, N, O or S. A "substitutable ring atom" is a ring carbon or nitrogen atom that is bonded to at least one hydrogen atom. The hydrogen may optionally be replaced by a suitable substituent. Thus, the term "substitutable ring atom" does not include ring nitrogen or carbon atoms that are shared when two rings are fused. In addition, when the structure depicts that a ring carbon or nitrogen atom is attached to one or more parts other than hydrogen and there is no hydrogen available for replacement, a "substitutable ring atom" does not include a ring carbon or nitrogen atom.
[0076] "Heteroatom" refers to one or more of oxygen, sulfur, nitrogen, including nitrogen, any oxidized form of sulfur, the quaternized form of any basic nitrogen, or a substitutable nitrogen of a heterocyclic or heteroaryl ring, such as N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR + (as in N-substituted pyrrolidinyl).
[0077] In some embodiments, a variable that occurs independently twice can be taken together with the atom to which each variable is bound to form a 5- to 8-membered aryl or heteroaryl ring or a 3- to 8-membered alicyclic ring (e.g., a 4- to 6-membered cycloalkyl) or heterocyclyl. Exemplary rings formed when a substituent that occurs independently twice is taken together with the atom to which each variable is bound include, but are not limited to, the following: a) a substituent that occurs independently twice is bound to the same atom and forms a ring with that atom, wherein both occurrences of the substituent are taken together with the atom to which they are bound to form a heterocyclyl, heteroaryl, alicyclic, or aryl ring, wherein the group is attached to the rest of the molecule through a single point of attachment; and b) a substituent that occurs independently twice is bound to different atoms and forms a heterocyclyl, heteroaryl, alicyclic, or aryl ring with the two atoms, wherein the ring formed has two points of attachment to the rest of the molecule.
[0078] It is understood that a variety of other rings may be formed when two independent occurrences of a substituent are taken together with the atoms to which each substituent is bound, and that the examples detailed above are not intended to be limiting.
[0079] As described herein, a bond drawn from a substituent to the center of one ring within a polycyclic system (as shown below) represents substitution of the substituent at any substitutable position of any of the rings within the polycyclic system. For example, Formula D3 represents possible substitution in any of the positions shown in Formula D4:
[0080]
[0081] However, if two rings in a polycyclic system each have different substituents drawn from the center of each ring, then unless otherwise specified, each substituent represents substitution only on the ring to which it is attached. For example, in formula D6, Y is an optional substituent for only ring A, and X is an optional substituent for only ring B.
[0082]
[0083] As used herein, the term "alkoxy" refers to an alkyl group as previously defined, attached to a molecule or to another chain or ring through an oxygen ("alkoxy" i.e. -O-alkyl) atom. The term "alkenyloxy" refers to an alkenyl group as previously defined, attached to a molecule or to another chain or ring through an oxygen ("alkenyloxy" i.e. -O-alkenyl) atom.
[0084] As used herein, the terms "halo," "halogen," and "halide" refer to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).
[0085] The terms "haloalkyl", "haloalkenyl", "haloaliphatic" and "haloalkoxy" refer to alkyl, alkenyl, aliphatic or alkoxy groups that are optionally substituted with one or more halogen atoms. 1-3 The haloalkyl group may be -CFHCH2CHF2 and C 1-2 A haloalkoxy group may be -OC(Br)HCHF2. This term includes perfluoroalkyl groups such as -CF3 and -CF2CF3.
[0086] As used herein, the term "cyano" refers to -CN or -C≡N.
[0087] The term "hydroxyl" or "hydroxy" refers to -OH.
[0088] As used herein, "carbonyl" used alone or in combination with another group refers to -C(O)- or -C(O)H. For example, as used herein, "alkoxycarbonyl" refers to groups such as -C(O)O(alkyl).
[0089] As used herein, "oxo" refers to =0, where an oxo group is typically, but not always, attached to a carbon atom (e.g., it can also be attached to a sulfur atom). An aliphatic chain may optionally be interrupted by carbonyl groups or may optionally be substituted with oxo groups, and both representations refer to the same: for example, -CH2-C(O)-CH3. When "oxo" is listed as a possible substituent on a ring or another moiety or group (e.g., an alkyl chain), it is understood that the bond between the oxygen in the oxo group and the ring or moiety to which it is attached will be a double bond, although it may sometimes be generally drawn with a single line.
[0090] As used herein, a "carboxylic acid" is an organic compound containing a carboxyl (-C(=O)-OH) group.
[0091] As used herein, "activated ester" refers to an ester group that is easily displaced by an amino group or a guanylhydrazone group. For example, activated ester groups mainly have -C(=O)OE' groups, where -OE' is a good leaving group that can be easily displaced. For example, -OE' is selected from -O-(CH2CF3), -O-(nitrophenyl) (e.g., 2-nitrophenyl or 4-nitrophenyl), -O-(dinitrophenyl) (e.g., 2,4-dinitrophenyl ester), -O-(trichlorophenyl) (e.g., 2,4,5-trichlorophenyl), -O-(pentafluorophenyl), -O-(sulfo-tetrafluorophenyl) (e.g., 4-sulfo-2,3,5,6-tetrafluorophenyl), -O-(succinimidyl), -O-(benzotriazole), -O-(7-azabenzotriazole), -O-(phthalimido), -O-(5-norbornene-endo-2,3-dicarboximide) or -O-(sulfo-succinimidyl). Specifically, -OE' is -O-(CH2CF3). In one embodiment, the activated ester is CF3C(=O)OCH2CF3.
[0092] As used herein, "thioester" refers to a thioester group that is easily displaced by an amino group or a guanylhydrazone group. For example, the thioester group mainly has a -C(=O)SR' group, wherein -SR' is a good leaving group that can be easily displaced.
[0093] As used herein, "acyl halide" is an organic compound containing -C(=O)-X, wherein X is a halogen.
[0094] As used herein, "thioacyl halide" is an organic compound containing -C(=S)-X, wherein X is a halogen.
[0095] As used herein, an "anhydride" is an organic compound having two acyl groups bonded to the same oxygen atom. Also included are mixed anhydrides in which one of the two acyl groups is derived from phosphoric acid, phosphonic acid, or an oxime group.
[0096] As used herein, "guanylhydrazone" is an organic compound containing a -C(=NH)-NH-NH- moiety.
[0097] As used herein, a "base" is a compound that donates electrons or hydroxide ions or accepts protons. Exemplary bases may include, but are not limited to, trialkylamines (e.g., trimethylamine), alkoxides (e.g., NaOMe), alkali metal hydroxides (e.g., LiOH, NaOH, or KOH), alkaline earth metal hydroxides, carbonates, phosphazenes, 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), guanidine, 1,1,3,3-tetramethylguanidine, optionally substituted pyridines (e.g., 4-dimethylaminopyridine (DMAP)), or 1,4-diazabicyclo[2.2.2]-octane (DABCO). In one embodiment, the base is selected from an amine, an amidine, a guanidine, a substituted pyridine, or a phosphazene base. In particular, the base is an amine, amidine, guanidine or substituted pyridine base and is selected from a trialkylamine such as trimethylamine, 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), guanidine, 1,1,3,3-tetramethylguanidine, an optionally substituted pyridine such as 4-dimethylaminopyridine (DMAP) or 1,4-diazabicyclo[2.2.2]-octane (DABCO). In one embodiment, the base is selected from trialkylamines, carbonates, phosphazenes, 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), guanidine, 1,1,3,3-tetramethylguanidine, optionally substituted pyridine or 1,4-diazabicyclo[2.2.2]-octane (DABCO). In one embodiment, the base is DMAP. In another embodiment, the base is DABCO.
[0098] In addition, exemplary bases may include alkali metal hydroxides (e.g., NaOH, KOH, and LiOH), alkali metal alkoxides (e.g., NaOMe, NaOEt, KOMe, and KOEt). In one embodiment, the second base is selected from trialkylamines (e.g., trimethylamine), alkoxides (e.g., NaOMe, NaOEt, KOMe, KOEt, potassium tert-butoxide), alkali metal hydroxides (e.g., LiOH, NaOH, or KOH), alkaline earth metal hydroxides, and carbonates (e.g., calcium carbonate, cesium carbonate, potassium carbonate). In one embodiment, the second base is NaOMe. In another embodiment, the second base is KOMe.
[0099] The term "protecting group" or "protecting moiety" refers to a substituent, a derivative thereof, or a combination thereof, which is usually used to block or protect a specific functional group when other functional groups on a compound react. For example, a "guanylhydrazone protecting group" is a substituent of a guanylhydrazone functional group in a blocking or protecting compound attached to a guanylhydrazone-NH-group. Commonly used amino protecting groups can be used as guanylhydrazone protecting groups. Such amino protecting groups are also well known in the art (see, for example, P. Wuts and T. Greene, 2007, Protective Groups in Organic Synthesis, Chapter 7, J. Wiley & Sons, NJ). Suitable guanylhydrazone protecting groups include, but are not limited to, carbamate amino protecting groups, amide amino protecting groups, or sulfonyl amino protecting groups. For example, the guanylhydrazone protecting group is selected from the group consisting of tert-butyloxycarbonyl (Boc), 2,2,2-trichloroethoxycarbonyl (Troc), benzyloxycarbonyl (Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), methylsulfonyl, p-toluenesulfonyl (Tos), 4-nitrobenzenesulfonyl (NOSyl), 2-nitrobenzenesulfonyl, p-bromobenzenesulfonyl (Brosyl), trifluoroacetyl, acetyl, benzoyl, 2-trimethylsilylethyl, (2-phenyl-2-trimethylsilyl)ethyl, triisopropylsiloxy, 2-(trimethylsilyl)ethoxymethyl, allyloxycarbonyl, and 2-(trimethylsilyl)ethoxycarbonyl. For a general description of protecting groups and their uses, see PGM Wuts and TW Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 2007.
[0100] As used herein, the term "guanylhydrazone deprotecting agent" refers to a reagent that can decompose a guanylhydrazone protecting group to form a free guanylhydrazone. Commonly used amine deprotecting agents can be used as guanylhydrazone deprotecting agents. Such amine deprotecting groups are well known in the art (see, for example, P. Wuts and T. Greene, 2007, Protective Groups in Organic Synthesis, Chapter 2, J. Wiley & Sons, NJ). In some embodiments, the guanylhydrazone deprotecting agent is selected from acids, fluorine-containing reagents, silicon-containing reagents, metal-containing reagents, and amines. Examples of metals in metal-containing reagents are zinc, cadmium, nickel, palladium, cobalt, aluminum, and mercury, etc. Examples of such guanylhydrazone deprotecting agents include, but are not limited to, tetra-n-butylammonium fluoride, tris(dimethylamino)sulfonium difluorotrimethylsilicate, hydrogen fluoride or its solvate, hydrogen fluoride pyridine, silicon tetrafluoride, hexafluorosilicic acid, cesium fluoride, hydrochloric acid, acetic acid, trifluoroacetic acid, pyridinium p-toluenesulfonate, p-toluenesulfonic acid (p-TsOH), formic acid, periodic acid, piperidine, morpholine, pyridine, hydrazine, trimethylsilyl iodide, phosphoric acid, and trifluoroacetic acid. In certain embodiments, the guanylhydrazone deprotecting agent is selected from tetra-n-butylammonium fluoride, acetic acid, hydrogen fluoride pyridine, cesium fluoride, piperidine, morpholine, pyridine, hydrazine, trimethylsilyl iodide, and trifluoroacetic acid.
[0101] As used herein, "activator" refers to a reagent or moiety that increases the reactivity of a guanylhydrazone group, increases the reactivity of a carbonyl group, and / or activates a hydroxyl group to promote the coupling reaction between a carboxylic acid and a guanylhydrazone group. Examples of such activators or moieties include carbodiimides, uroniums, active esters, phosphoniums, 2-alkyl-1-alkylcarbonyl-1,2-dihydroquinolines, 2-alkoxy-1-alkoxycarbonyl-1,2-dihydroquinolines, ethyl cyanohydroxyiminoacetate ... and alkyl chloroformate. In a particular embodiment, the activator is a carbodiimide. In a more particular embodiment, the activator is dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), or diisopropylcarbodiimide (DIC). In another particular embodiment, the activator is N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. In another embodiment, the activator is selected from ethyl chloroformate and 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EDDQ). In another embodiment, the activator is a uronium, such as O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) or its tetrafluoroborate equivalent TBTU.
[0102] As used herein, the term "salt" refers to an organic or inorganic salt of a compound of the invention. Exemplary salts include, but are not limited to, sulfates, citrates, acetates, oxalates, chlorides, bromides, iodides, nitrates, bisulfates, phosphates, acid phosphates, isonicotinates, lactates, salicylates, acid citrates, tartrates, oleates, tannates, pantothenates, bitartrates, ascorbates, succinates, maleates, gentisates, fumarates, gluconates, glucuronates, glucarates, formates, benzoates, glutamates, methanesulfonates ("mesylate"), ethanesulfonates, benzenesulfonates, p-toluenesulfonates, pamoates (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)), alkali metal (e.g., sodium and potassium) salts, alkaline earth metal (e.g., magnesium) salts, and ammonium salts. A salt may involve the inclusion of another molecule, such as an acetate ion, a succinate ion, or other counterion. The counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. In addition, a salt may have more than one charged atom in its structure. Individual instances where multiple charged atoms are part of a salt may have multiple counterions. Thus, a salt may have one or more charged atoms and / or one or more counterions.
[0103] The term "leaving group" refers to a group having a charged or uncharged portion that leaves during nucleophilic or electrophilic substitution or displacement. Such leaving groups are well known in the art and include, but are not limited to, halogens, esters, oxime esters, alkoxy, hydroxyl, tosylate, triflate, mesylate, nitrile, azide, carbamate, disulfide, thioester, thioether, and diazo compounds.
[0104] Method of the present invention
[0105] The present invention provides a novel process for preparing 3-substituted 1,2,4-triazole compounds.
[0106] In the first aspect, the second embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by the following formula IB:
[0107]
[0108] or a salt thereof. The method comprises reacting a guanylhydrazone compound represented by the following formula IIB in the presence of a base:
[0109]
[0110] or its salts with R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR' or R11 C(O)OR" reaction, in which when R 11 C(O)OH, an activator is also present. Formula IB, Formula IIB, R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR′ and R 11 The values of the variables in C(O)OR" are as defined for the first embodiment of the first aspect.
[0111] In the first aspect, the third embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by the following formula IC:
[0112]
[0113] or a salt thereof. The method comprises reacting a guanylhydrazone compound represented by the following formula IIC in the presence of a base:
[0114]
[0115] or its salts with R 11 C(O)OH、R 11 C(O)X′、R 11 C(S)X′、R 11 C(O)OE′、R 11 C(O)SR′ or R 11 C(O)OR" reaction, in which when R 11 C(O)OH, an activator is also present. Formula IC, Formula IIC, R 11 C(O)OH、R 11 C(O)X′、R 11 C(S)X′、R 11 C(O)OE′、R 11 C(O)SR' and R 11 The values of the variables in C(O)OR" are as defined for the first embodiment of the first aspect.
[0116] In the first aspect, the fourth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by the following formula ID:
[0117]
[0118] or a salt thereof. The method comprises reacting a guanylhydrazone compound represented by the following formula IID in the presence of a base:
[0119]
[0120] or its salts with R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR' or R 11 C(O)OR" reaction, in which when R 11 C(O)OH, an activator is also present. In this embodiment, Y in Formula ID and Formula IID is N or C; and Formula ID, Formula IID, R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE′、R 11 C(O)SR′ and R 11 The values of the other variables in C(O)OR" are as defined for the first embodiment of the first aspect.
[0121] In the first aspect, the fifth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by the following formula IE:
[0122]
[0123] or a salt thereof. The method comprises reacting a guanylhydrazone compound represented by the following formula IIE in the presence of a base:
[0124]
[0125] or its salts with R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR' or R 11 C(O)OR" reaction, in which when R 11 C(O)OH, an activator is also present. In this embodiment, Formula IE, Formula IIE, R 11 C(O)OH、R 11 C(O)X′、R 11 C(S)X′、R 11 C(O)OE′、R 11 C(O)SR′ and R 11 The values of the variables in C(O)OR" are as defined in the first and / or fourth embodiment of the first aspect.
[0126] In the first aspect, the sixth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by the following formula IF:
[0127]
[0128] or a salt thereof. The method comprises reacting a guanylhydrazone compound represented by the following formula IIF in the presence of a base:
[0129]
[0130] or its salts with R 11 C(O)OH、R 11 C(O)X′、R 11 C(S)X′、R 11 C(O)OE′、R 11 C(O)SR' or R 11 C(O)OR" reaction, in which when R 11 C(O)OH, an activator is also present. In this embodiment, R 11 is CF3 and of formula IIF, R 11 C(O)OH、R 11 C(O)X′、R 11 C(S)X'、R 11 C(O)OE′、R 11 C(O)SR′ and R 11 The values of the other variables in C(O)OR" are as defined for the first embodiment of the first aspect.
[0131] In the first aspect, the seventh embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by the following formula IG:
[0132]
[0133] or a salt thereof. The method comprises reacting a guanylhydrazone compound represented by the following formula IIG in the presence of a base:
[0134]
[0135] or its salts with R 11 C(O)OH、R 11 C(O)X′、R 11 C(S)X′、R 11 C(O)OE'、R 11 C(O)SR′ or R 11 C(O)OR" reaction, in which when R 11 C(O)OH, an activator is also present. In this embodiment, X is C or N; and Formula IG, Formula IIG, R 11C(O)OH、R 11 C(O)X'、R 11 C(S)X′、R 11 C(O)OE′、R 11 C(O)SR' and R 11 The values of the other variables in C(O)OR" are as defined for the first embodiment of the first aspect.
[0136] In the first aspect, the eighth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by the following formula IH:
[0137]
[0138] or a salt thereof. The method comprises reacting a guanylhydrazone compound represented by the following formula IIH in the presence of a base:
[0139]
[0140] or its salts with R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X′、R 11 C(O)OE′、R 11 C(O)SR′ or R 11 C(O)OR" reaction, in which when R 11 C(O)OH, an activator is also present. In this embodiment, Formula IH, Formula IIH, R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X′、R 11 C(O)OE′、R 11 C(O)SR′ and R 11 The values of the variables in C(O)OR" are as defined in the first and / or seventh embodiment of the first aspect.
[0141] In the first aspect, the ninth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by the following formula IJ:
[0142]
[0143] or a salt thereof. The method comprises reacting a guanylhydrazone compound represented by the following formula IIJ in the presence of a base:
[0144]
[0145] or its salts with R 11 C(O)OH、R 11 C(O)X′、R 11C(S)X′、R 11 C(O)OE'、R 11 C(O)SR' or R 11 C(O)OR" reaction, in which when R 11 C(O)OH, an activator is also present. In this embodiment, Formula IJ, Formula IIJ, R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR' and R 11 The values of the variables in C(O)OR" are as defined for the first embodiment of the first aspect.
[0146] In the first aspect, the tenth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by the following formula IL:
[0147]
[0148] or a salt thereof. The method comprises reacting a guanylhydrazone compound represented by the following formula IIL in the presence of a base:
[0149]
[0150] or its salts with R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR' or R 11 C(O)OR" reaction, in which when R 11 C(O)OH, an activator is also present. In this embodiment, Formula IL, Formula IIL, R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X′、R 11 C(O)OE′、R 11 C(O)SR′ and R 11 The values of the variables in C(O)OR" are as defined for the first embodiment of the first aspect.
[0151] In the first aspect, the eleventh embodiment is a method of preparing a 3-substituted 1,2,4-triazole compound represented by Formula IA, IB, IC, ID, IG, IJ or a salt thereof as described in the first, second, third, fourth, seventh or ninth embodiment of the first aspect. Ring B in Formula IA, IIA, IB, IIB, IC, IIC, ID, IID, IG, IIG, IJ and IIJ is phenyl or a 5-membered or 6-membered heteroaryl ring containing 1 or 2 ring nitrogen atoms, and the values of the other variables are as defined for the first, fourth and / or seventh embodiment of the first aspect.
[0152] In the first aspect, the twelfth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound or a salt thereof represented by Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment of the first aspect. Formula IA, IIA, IIB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL and IIL, R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR′ and R 11 J in C(O)OR" B , J C , p and R 11 Further defined as follows:
[0153] J B is independently halo or C optionally substituted with up to 3 halo 1-6 alkyl;
[0154] When present, each J C independently selected from hydrogen, halo, -CN, and C optionally and independently substituted with up to 3 halo 1-4 alkyl;
[0155] When present, p is 1 or 2;
[0156] R 11 H; -NR a2 R b2 ;-C(O)NR a2 R b2 ;-C(O)R 15a ; -CN; optionally and independently 0 to 3 R 15 Substituted C 1-6 Alkyl; optionally and independently 0 to 2 Rb2 Substituted C 2-6 optionally and independently 0 to 2 R b2 Substituted C 2-6 Alkynyl; optionally and independently 0 to 5 R 15 Substituted C 1-6 Alkoxy; optionally and independently 0 to 3 R 15 substituted phenyl; optionally and independently substituted with 0 to 3 R 15 substituted 5- to 6-membered heteroaryl; optionally and independently substituted with 0 to 3 R 15 Substituted C 3-8 Cycloalkyl or optionally and independently substituted with 0 to 3 R 15 substituted 3- to 8-membered heterocyclyl; wherein each of the 5- to 6-membered heteroaryl and each of the 3- to 8-membered heterocyclyl contains up to 3 ring heteroatoms independently selected from N, O or S;
[0157] R 15 Halogen, -OR b2 、-SR b2 、-NR a2 R b2 、-C(O)R b2 、-C(O)NR a2 R b2 、-NR b2 C(O)OR b2 、-OC(O)NR a2 R b2 , C 2-4 Alkenyloxy, C 3-8 Cycloalkyl, phenyl, 5- or 6-membered heteroaryl, or 3- to 10-membered heterocyclyl; wherein each of the 5- or 6-membered heteroaryl rings and each of the 3- to 10-membered heterocyclyl contains up to 3 ring heteroatoms independently selected from N, O, or S;
[0158] R 15a C 3-8 Cycloalkyl, phenyl, 5- or 6-membered heteroaryl, or 3- to 10-membered heterocyclyl; wherein each of the 5- or 6-membered heteroaryl rings and each of the 3- to 10-membered heterocyclyl contains up to 3 ring heteroatoms independently selected from N, O, or S; and
[0159] R a2 For hydrogen, C 1-6 Alkyl or C 1-6 haloalkyl; and
[0160] R b2 For hydrogen, C 1-6 Alkyl or C 1-6 Halogenated alkyl.
[0161] Formula IA, IIA, IB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL and IIL, R 11 C(O)X'、R 11 C(S)X′、R 11 C(O)OE'、R 11 C(O)SR′ and R 11 The values of the other variables in C(O)OR" are as defined for the first, fourth, seventh and / or eleventh embodiment of the first aspect.
[0162] In the first aspect, the thirteenth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound or a salt thereof represented by Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment of the first aspect. Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ and IL, R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR' and R 11 R in C(O)OR" 11 For-NR a2 R b2 ; C optionally and independently substituted with 0 to 3 halo 1-6 alkyl; 5- to 6-membered heteroaryl optionally and independently substituted with 0 to 3 halogen groups or C 3-8 Cycloalkyl. B and J C As defined in the twelfth embodiment of the first aspect. Formula IA, IIA, IB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL and IIL, R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR' and R 11 The values of the other variables in C(O)OR" are as defined in the first, fourth and / or seventh embodiment of the first aspect.
[0163] In the first aspect, the fourteenth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound or a salt thereof represented by Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment of the first aspect. Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ and IL, R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR' and R 11 R in C(O)OR" 11 is C optionally and independently substituted with 0 to 3 halo 1-6 Alkyl. B and J C As defined in the twelfth embodiment of the first aspect. Formula IA, IIA, IB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL and IIL, R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR' and R 11 The values of the other variables in C(O)OR" are as defined in the first, fourth and / or seventh embodiment of the first aspect.
[0164] In the first aspect, the fifteenth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound or a salt thereof represented by Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment of the first aspect. Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ and IL, R 11 C(O)OH、R 11 C(O)X′、R 11 C(S)X'、R 11 C(O)OE′、R 11 C(O)SR′ and R 11 R in C(O)OR" 11 is CF3. B and J CAs defined in the twelfth embodiment of the first aspect. Formula IA, IIA, IB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL and IIL, R 11 C(O)X′、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR' and R 11 The values of the other variables in C(O)OR" are as defined in the first, fourth and / or seventh embodiment of the first aspect.
[0165] In the first aspect, the sixteenth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound or a salt thereof represented by Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment of the first aspect. G in Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ and IIL 1 is a carbamate amino protecting group, an amide amino protecting group or a sulfonyl amino protecting group. Formula IA, IIA, IB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL and IIL, R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X′、R 11 C(O)OE′、R 11 C(O)SR′ and R 11 The values of the other variables in C(O)OR" are as defined in the first, fourth, seventh, eleventh, twelfth, thirteenth, fourteenth and / or fifteenth embodiment of the first aspect.
[0166] In the first aspect, the seventeenth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound or a salt thereof represented by Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment of the first aspect. G in Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ and IIL 1is tert-butyloxycarbonyl (Boc), 2,2,2-trichloroethoxycarbonyl (Troc), benzyloxycarbonyl (Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), methylsulfonyl, p-toluenesulfonyl (Tos), 4-nitrobenzenesulfonyl (NOSyl), 2-nitrobenzenesulfonyl, p-bromobenzenesulfonyl (Brosyl), trifluoroacetyl, acetyl or benzoyl. Formula IA, IIA, IB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL and IIL, R 11 C(O)OH、R 11 C(O)X′、R 11 C(S)X′、R 11 C(O)OE′、R 11 C(O)SR′ and R 11 The values of the other variables in C(O)OR" are as defined in the first, fourth, seventh, eleventh, twelfth, thirteenth, fourteenth and / or fifteenth embodiment of the first aspect.
[0167] In the first aspect, the eighteenth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL or a salt thereof as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment of the first aspect, comprising reacting a guanylhydrazone compound represented by Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIL or a salt thereof with R in the presence of a base. 11 C(O)OE' reaction, where -OE' is -O-(C 1-6 Alkyl), -O-(C 1-6 wherein phenyl, heteroaryl and heterocyclyl are optionally substituted with 1 to 6 groups independently selected from halo, cyano, nitro, oxo, SO3H and SO3C 1-6 The values of the other variables in Formulas IA, IIA, IB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL, and IIL are as defined for the first, fourth, seventh, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, and / or seventeenth embodiment of the first aspect.
[0168] In the first aspect, the nineteenth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL or a salt thereof as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment of the first aspect, comprising reacting a guanylhydrazone compound represented by Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIL or a salt thereof with R in the presence of a base. 11 C(O)OE' reaction, where -OE' is -O-(C 1-6 The values of the other variables in Formulas IA, IIA, IB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL, and IIL are as defined for the first, fourth, seventh, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, and / or seventeenth embodiment of the first aspect.
[0169] In the first aspect, the twentieth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL or a salt thereof as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment of the first aspect, comprising reacting a guanylhydrazone compound represented by Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIL or a salt thereof with R in the presence of a base. 11 C(O)OE' reaction, wherein -OE' is -O-(CH2CF3), -O-(nitrophenyl) (e.g., 2-nitrophenyl or 4-nitrophenyl), -O-(dinitrophenyl) (e.g., 2,4-dinitrophenyl ester), -O-(trichlorophenyl) (e.g., 2,4,5-trichlorophenyl), -O-(pentafluorophenyl), -O-(sulfo-tetrafluorophenyl) (e.g., 4-sulfo-2,3,5,6-tetrafluorophenyl), -O-(succinimidyl), -O-(benzotriazole), -O-(7-azabenzotriazole), -O-(phthalimido), -O-(5-norbornene-endo-2,3-dicarboximide) or -O-(sulfo-succinimidyl). The values of the other variables in Formulas IA, IIA, IB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL and IIL are as defined for the first, fourth, seventh, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth and / or seventeenth embodiment of the first aspect.
[0170] In the first aspect, the twenty-first embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL or a salt thereof as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment of the first aspect, comprising reacting a guanylhydrazone compound represented by Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIL or a salt thereof with R in the presence of a base. 11 C(O)OR" reaction, where R" is N=CR 11b R 11c The values of the other variables in Formulas IA, IIA, IB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL, and IIL are as defined for the first, fourth, seventh, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, and / or seventeenth embodiment of the first aspect.
[0171] In the first aspect, the twenty-second embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL or a salt thereof as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment of the first aspect, comprising reacting a guanylhydrazone compound represented by Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIL or a salt thereof with R in the presence of a base in the presence of an activator. 11 The values of the other variables in Formulas IA, IIA, IB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL, and IIL are as defined for the first, fourth, seventh, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, and / or seventeenth embodiment of the first aspect.
[0172] In the first aspect, the twenty-third embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL or a salt thereof as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment of the first aspect, comprising reacting a guanylhydrazone compound represented by Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIL or a salt thereof with R in the presence of a base in the presence of an activator. 11C(O)OH reaction, wherein the activator is carbodiimide, uronium, phosphonium, 2-alkyl-1-alkylcarbonyl-1,2-dihydroquinoline, 2-alkoxy-1-alkoxycarbonyl-1,2-dihydroquinoline, cyanohydroxyiminoacetic acid ethyl ester The values of the other variables in Formulas IA, IIA, IB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL, and IIL are as defined for the first, fourth, seventh, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, and / or seventeenth embodiment of the first aspect.
[0173] In the first aspect, the twenty-fourth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL or a salt thereof as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment of the first aspect, comprising reacting a guanylhydrazone compound represented by Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIL or a salt thereof with R in the presence of a base. 11 C(O)SR' reaction, where -SR' is -S-(aryl), -S-(C 1-20 The values of the other variables in Formulas IA, IIA, IB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL, and IIL are as defined for the first, fourth, seventh, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, and / or seventeenth embodiment of the first aspect.
[0174] In the first aspect, the twenty-fifth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL or a salt thereof as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment of the first aspect, comprising reacting a guanylhydrazone compound represented by Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIL or a salt thereof with R in the presence of a base. 11C(O)SR′ reaction, wherein —SR′ is —S—(ethyl), —S—(dodecyl), —S—(p-chlorophenyl), or —S—(2-benzothiazolyl). The values of the other variables in Formulas IA, IIA, IB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL, and IIL are as defined for the first, fourth, seventh, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, and / or seventeenth embodiment of the first aspect.
[0175] In the first aspect, the twenty-sixth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL or a salt thereof as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment of the first aspect, comprising reacting a guanylhydrazone compound represented by Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIL or a salt thereof with R in the presence of a base. 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE′、R 11 C(O)SR′ or R 11 C(O)OR" reaction, in which when R 11 C(O)OH, an activator is also present, wherein the base is selected from: trialkylamines, carbonates, phosphazenes, 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), guanidine, 1,1,3,3-tetramethylguanidine, optionally substituted pyridine or 1,4-diazabicyclo[2.2.2]-octane (DABCO), or in specific embodiments, the base is selected from: trialkylamines, phosphazenes, 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), guanidine, 1,1,3,3-tetramethylguanidine, optionally substituted pyridine or 1,4-diazabicyclo[2.2.2]-octane (DABCO). Formula IA, IIA, IB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL and IIL, R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR' and R11 The values of the other variables in C(O)OR" are as defined in the first, fourth, seventh, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth and / or twenty-fifth embodiment of the first aspect.
[0176] In the first aspect, the twenty-seventh embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL or a salt thereof as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment of the first aspect, comprising reacting a guanylhydrazone compound represented by Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIL or a salt thereof with R in the presence of a base. 11 C(O)OH、R 11 C(O)X′、R 11 C(S)X′、R 11 C(O)OE′、R 11 C(O)SR′ or R 11 C(O)OR" reaction, in which when R 11 C(O)OH, an activator is also present, wherein the base is 4-dimethylaminopyridine (DMAP). Formula IA, IIA, IB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL and IIL, R 11 C(O)OH、R 11 C(O)X′、R 11 C(S)X′、R 11 C(O)OE′、R 11 C(O)SR′ and R 11 The values of the other variables in C(O)OR" are as defined in the first, fourth, seventh, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth and / or twenty-fifth embodiment of the first aspect.
[0177] In the first aspect, the twenty-eighth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL or a salt thereof as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment of the first aspect, comprising reacting the seventh, eighth, ninth or tenth embodiment of the first aspect, comprising reacting a guanylhydrazone compound represented by formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIL or a salt thereof with R in the presence of a base. 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR' or R 11 C(O)OR" reaction, in which when R 11 C(O)OH, an activator is also present, wherein the base is DABCO. Formula IA, IIA, IB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL and IIL, R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR' and R 11 The values of the other variables in C(O)OR" are as defined in the first, fourth, seventh, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth and / or twenty-fifth embodiment of the first aspect.
[0178] In the first aspect, the twenty-ninth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound or a salt thereof represented by formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment of the first aspect. The method further comprises reacting the guanylhydrazone compound with a carboxylic acid, an acyl halide, a thioacyl halide, an activated ester, a thioester or an acid anhydride, and optionally reacting the reaction product with a guanylhydrazone deprotecting agent to deprotect the guanylhydrazone protecting group. Formula IA, IIA, IB, IIB, IC, IIC, ID, IID, IE, IIE, IF, IIF, IG, IIG, IH, IIH, IJ, IIJ, IL and IIL, R 11 C(O)OH、R 11C(O)X'、R 11 C(S)X′、R 11 C(O)OE'、R 11 C(O)SR'、R 11 The values of the variables in C(O)OR" and base are as defined for the first, fourth, seventh, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh and / or twenty-eighth embodiment of the first aspect.
[0179] In the first aspect, the thirtieth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by formula IA or a salt thereof as described in the first embodiment of the first aspect, comprising reacting a guanylhydrazone compound represented by formula IIA or a salt thereof with R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE′、R 11 C(O)SR' or R 11 C(O)OR" reaction, in which when R 11 C(O)OH, an activator is also present. The guanylhydrazone compound represented by formula IIA or a salt thereof is prepared by a method comprising: reacting a compound of formula IIIA in a reaction solvent:
[0180]
[0181] or a salt thereof,
[0182] First react with the second base, then react with the formula H2NNHG 1 Compounds of formula IA, IIA, IIIA, R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR'、R 11 C(O)OR" and H2NNHG 1 The values of the variables in are as defined for the first embodiment of the first aspect. In one embodiment, the compound represented by formula IIIA or a salt thereof is a compound of formula IIIB below:
[0183]
[0184] Formula IA, IIA, IIIB, R 11 C(O)OH、R 11C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR'、R 11 C(O)OR" and H2NNHG 1 The values of the variables in are as defined for the first embodiment of the first aspect. In one embodiment, the compound represented by formula IIIA or a salt thereof is a compound of formula IIIC:
[0185]
[0186] Formula IA, IIA, IIIC, R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR'、R 11 C(O)OR" and H2NNHG 1 The values of the variables in are as defined for the first embodiment of the first aspect. In one aspect, the compound represented by formula IIIA or a salt thereof is a compound of formula IIID below:
[0187]
[0188] Formula IA, IIA, IIID, R 11 C(O)OH、R 11 C(O)X′、R 11 C(S)X′、R 11 C(O)OE′、R 11 C(O)SR′、R 11 C(O)OR" and H2NNHG 1 The values of the variables in are as defined for the first embodiment of the first aspect. In one aspect, the compound represented by formula IIIA or a salt thereof is a compound of formula IIIE:
[0189]
[0190] Formula IA, IIA, IIIE, R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE′、R 11 C(O)SR′、R 11 C(O)OR" and H2NNHG 1The values of the variables in are as defined for the first embodiment of the first aspect. In one aspect, the compound represented by formula IIIA or a salt thereof is a compound of formula IIIF below:
[0191]
[0192] Formula IA, IIA, IIIF, R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR'、R 11 C(O)OR" and H2NNHG 1 The values of the variables in are as defined for the first embodiment of the first aspect. In certain embodiments, for Formula IIIA, IIIB, IIIC, IIID, IIIE or IIIF described above, W is Ring B, which is phenyl or a 5-membered or 6-membered heteroaryl ring containing 1 or 2 ring nitrogen atoms. More specifically, W is phenyl. In certain embodiments, for Formula IIIA, IIIB, IIIC, IIID, IIIE or IIIF described above, J B is independently halo or C1-6 alkyl optionally substituted with up to 3 halo groups;
[0193] When present, each J C independently selected from hydrogen, halo, -CN and C1-4 alkyl optionally and independently substituted with up to 3 halo; and when present, p is 1 or 2.
[0194] In the first aspect, the thirty-first embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by formula IA or a salt thereof as described in the first embodiment of the first aspect, comprising reacting a guanylhydrazone compound represented by formula IIA or a salt thereof with R 11 C(O)OH、R 11 C(O)X′、R 11 C(S)X′、R 11 C(O)OE′、R 11 C(O)SR' or R 11 C(O)OR" reaction, in which when R 11 C(O)OH, an activator is also present. The guanylhydrazone compound represented by formula IIA or a salt thereof is prepared as described in the 30th embodiment, which comprises reacting the compound of formula IIIA first with a second base and secondly with a compound of formula H2NNHG 1 The compound is reacted, wherein the reaction solvent is alcohol. Formula IA, IIA, IIIA, R 11 C(O)OH、R 11C(O)X'、R 11 C(S)X'、R 11 C(O)OE′、R 11 C(O)SR′、R 11 C(O)OR" and H2NNHG 1 The values of the variables in are as defined for the first embodiment of the first aspect.
[0195] In the first aspect, the thirty-second embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by formula IA or a salt thereof as described in the first embodiment of the first aspect, comprising reacting a guanylhydrazone compound represented by formula IIA or a salt thereof with R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X′、R 11 C(O)OE′、R 11 C(O)SR′ or R 11 C(O)OR" reaction, in which when R 11 C(O)OH, an activator is also present. The guanylhydrazone compound represented by formula IIA or a salt thereof is prepared as described in the 30th embodiment, which comprises reacting the compound of formula IIIA first with a second base and secondly with a compound of formula H2NNHG 1 The compound is reacted, wherein the reaction solvent is MeOH. Formula IA, IIA, IIIA, R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR'、R 11 C(O)OR" and H2NNHG 1 The values of the variables in are as defined for the first embodiment of the first aspect.
[0196] In the first aspect, the thirty-third embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by formula IA or a salt thereof as described in the first embodiment of the first aspect, comprising reacting a guanylhydrazone compound represented by formula IIA or a salt thereof with R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR' or R 11 C(O)OR" reaction, in which when R 11C(O)OH, an activator is also present. The guanylhydrazone compound represented by formula IIA or a salt thereof is prepared as described in the 30th, 31st, and 32nd embodiments, which comprises reacting the compound of formula IIIA first with a second base, and secondly with a compound of formula H2NNHG 1 Compound reaction, wherein the second base is NaOMe. Formula IA, IIA, IIIA, R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X′、R 11 C(O)OE′、R 11 C(O)SR′、R 11 C(O)OR" and H2NNHG 1 The values of the variables in are as defined for the first embodiment of the first aspect.
[0197] In the first aspect, the thirty-fourth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by formula IA or a salt thereof as described in the first embodiment of the first aspect, comprising reacting a guanylhydrazone compound represented by formula IIA or a salt thereof with R 11 C(O)OH、R 11 C(O)X′、R 11 C(S)X′、R 11 C(O)OE'、R 11 C(O)SR' or R 11 C(O)OR" reaction, in which when R 11 C(O)OH, an activator is also present. A guanylhydrazone compound represented by Formula IIA or a salt thereof is prepared as described in the 30th, 31st, 32nd or 33rd Example, Formula H2NNHG 1 The compound is H2NNHC(O)OC(CH3)3, H2NNHC(O)OCH2CCl3, H2NNHC(O)Obenzyl, H2NNHC(O)OCH2(9-fluorenyl), NH2NHSO2CH3, NH2NHSO2(p-toluene), NH2NHSO2(4-nitrophenyl), NH2NHSO2(2-nitrophenyl), NH2NHSO2(4-bromophenyl), NH2NHC(O)CF3, H2NNHC(O)phenyl or H2NNHC(O)CH3. Formula IA, IIA, IIIA, R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR' and R 11The values of the variables in C(O)OR" are as defined for the first embodiment of the first aspect.
[0198] In the first aspect, the thirty-fifth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by the following formula IF:
[0199]
[0200] or a salt thereof. The method comprises reacting a guanylhydrazone represented by the following formula IIFa in the presence of a base:
[0201]
[0202] Or its salt is reacted with CF3C(O)OCH2CF3.
[0203] In the first aspect, the thirty-sixth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by Formula IF or a salt thereof as described in the thirty-fifth embodiment of the first aspect. The base is DABCO.
[0204] In the first aspect, the thirty-seventh embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by Formula IF or a salt thereof as described in the thirty-fifth or thirty-sixth embodiment of the first aspect. The method further comprises purifying the 3-substituted 1,2,4-triazole compound of Formula IF by crystallization.
[0205] In the first aspect, the thirty-eighth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by Formula IF or a salt thereof as described in the thirty-fifth or thirty-sixth embodiment of the first aspect. The method further comprises purifying the 3-substituted 1,2,4-triazole compound of Formula IF by crystallization, wherein the crystallization is performed by adding n-heptane to the reaction mixture after the reaction between the guanylhydrazone compound represented by Formula IIFa and CF3C(O)OCH2CF3 is completed.
[0206] In the first aspect, the thirty-ninth embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by formula IF or a salt thereof as described in the thirty-fifth, thirty-sixth, thirty-seventh or thirty-eighth embodiment of the first aspect, comprising reacting a guanylhydrazone compound represented by formula IIFa or a salt thereof with CF3C(O)OCH2CF3 in the presence of a base. The guanylhydrazone compound represented by formula IIFa or a salt thereof is prepared by a method comprising: reacting a compound of formula IIIFa in a reaction solvent:
[0207]
[0208] Or a salt thereof is reacted first with a second base and secondly with a H2NNHC(O)OC(CH3)3 compound.
[0209] In the first aspect, the 40th embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by formula IF or a salt thereof as described in the 35th, 36th, 37th or 38th embodiment of the first aspect, which comprises reacting a guanylhydrazone compound represented by formula IIFa or a salt thereof with CF3C(O)OCH2CF3 in the presence of a base. The guanylhydrazone compound represented by formula IIFa or a salt thereof is prepared by the method described in the 39th embodiment, which comprises reacting a compound of formula IIIFa or a salt thereof first with a second base and secondly with H2NNHC(O)OC(CH3)3 in a reaction solvent, wherein the reaction solvent is an alcohol.
[0210] In the first aspect, the forty-first embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by formula IF or a salt thereof as described in the thirty-fifth, thirty-sixth, thirty-seventh or thirty-eighth embodiment of the first aspect, which comprises reacting a guanylhydrazone compound represented by formula IIFa or a salt thereof with CF3C(O)OCH2CF3 in the presence of a base. The guanylhydrazone compound represented by formula IIFa or a salt thereof is prepared by the method described in the thirty-ninth embodiment, which comprises reacting a compound of formula IIIFa or a salt thereof first with a second base and secondly with H2NNHC(O)OC(CH3)3 in a reaction solvent, wherein the reaction solvent is MeOH.
[0211] In the first aspect, the forty-second embodiment is a method for preparing a 3-substituted 1,2,4-triazole compound represented by formula IF or a salt thereof as described in the thirty-fifth, thirty-sixth, thirty-seventh or thirty-eighth embodiment of the first aspect, which comprises reacting a guanylhydrazone compound represented by formula IIFa or a salt thereof with CF3C(O)OCH2CF3 in the presence of a base. The guanylhydrazone compound represented by formula IIFa or a salt thereof is prepared by a method as described in the thirty-ninth, fortieth or forty-first embodiment, which comprises reacting a compound of formula IIIFa or a salt thereof first with a second base and secondly with H2NNHC(O)OC(CH3)3 in a reaction solvent, wherein the second base is NaOMe.
[0212] Any suitable organic solvent can be used for the reactions described herein. Exemplary solvents include, but are not limited to, dimethylformamide (DMF), dichloromethane (DCM), dichloroethane, tetrahydrofuran (THF), dimethylacetamide (DMA), ethyl acetate, isopropyl acetate (IPAC), methanol, ethanol, acetonitrile, acetone, and the like.
[0213] In one embodiment, the guanylhydrazone compound and R 11C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR' or R 11 The reaction between C(O)OR" was carried out in IPAC.
[0214] In some embodiments, the 3-substituted 1,2,4-triazole compound represented by Formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, IL or a salt thereof is purified by crystallization. In one embodiment, the crystallization is performed by adding a co-solvent to a solution containing the 3-substituted 1,2,4-triazole compound.
[0215] As used herein, "co-solvent" refers to a solvent in which the 3-substituted 1,2,4-triazole compound is insoluble or has low solubility. Exemplary co-solvents include, but are not limited to, heptane, hexane, cyclohexane, toluene, and the like.
[0216] Compounds of the present invention
[0217] In a second embodiment of the second aspect, the compound is represented by the following Formula IIB:
[0218]
[0219] or a salt thereof, wherein the values of the variables are as defined for the first embodiment of the second aspect.
[0220] In a third embodiment of the second aspect, the compound is represented by the following Formula IIC:
[0221]
[0222] or a salt thereof, wherein the values of the variables are as defined for the first embodiment of the second aspect.
[0223] In a fourth embodiment of the second aspect, the compound is represented by the following Formula IID:
[0224]
[0225] or a salt thereof, wherein Y is N or C; and the values of the other variables are as defined for the first embodiment of the second aspect.
[0226] In a fifth embodiment of the second aspect, the compound is represented by the following Formula IIE:
[0227]
[0228] or a salt thereof, wherein the values of the variables are as defined for the first and / or fourth embodiment of the second aspect.
[0229] In a sixth embodiment of the second aspect, the compound is represented by the following Formula IIF:
[0230]
[0231] or a salt thereof, wherein the values of the variables are as defined for the first embodiment of the second aspect.
[0232] In a seventh embodiment of the second aspect, the compound is represented by Formula IIG:
[0233]
[0234] or a salt thereof, wherein X is C or N; and the values of the other variables are as defined for the first embodiment of the second aspect.
[0235] In an eighth embodiment of the second aspect, the compound is represented by the following Formula IIH:
[0236]
[0237] or a salt thereof, wherein the values of the variables are as defined for the first and / or seventh embodiment of the second aspect.
[0238] In a ninth embodiment of the second aspect, the compound is represented by Formula IIJ:
[0239]
[0240] or a salt thereof, wherein the values of the variables are as defined for the first embodiment of the second aspect.
[0241] In a tenth embodiment of the second aspect, the compound is represented by Formula IIL:
[0242]
[0243] or a salt thereof,
[0244] The values of the variables are as defined in the first embodiment of the second aspect.
[0245] In an eleventh embodiment of the second aspect, the compound is represented by Formula IIA, IIB, IIC, IID, IIG, IIJ, or a salt thereof, wherein Ring B is phenyl or a 5- or 6-membered heteroaryl ring containing 1 or 2 ring nitrogen atoms; and wherein the values of the other variables are as defined for the first, fourth and / or seventh embodiment of the second aspect.
[0246] In a twelfth embodiment of the second aspect, the compound is represented by Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIL, or a salt thereof, wherein
[0247] JB is independently halo or C optionally substituted with up to 3 halo 1-6 alkyl;
[0248] When present, each J C independently selected from hydrogen, halo, -CN or C optionally and independently substituted with up to 3 halo 1-4 Alkyl; and
[0249] When present, p is 1 or 2; and
[0250] The values of other variables are as defined in the first, fourth, seventh and / or eleventh embodiment of the second aspect.
[0251] In a thirteenth embodiment of the second aspect, the compound is represented by Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIL, or a salt thereof, wherein G 1 is a carbamate amino protecting group, an amide amino protecting group or a sulfonyl amino protecting group; and wherein the values of the other variables are as defined for the first, fourth, seventh, eleventh and / or twelfth embodiment of the second aspect.
[0252] In a fourteenth embodiment of the second aspect, the compound is represented by Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIL, or a salt thereof, wherein G 1 is tert-butyloxycarbonyl (Boc), 2,2,2-trichloroethoxycarbonyl (Troc), benzyloxycarbonyl (Z), 9-fluorenylmethoxycarbonyl (Fmoc), methylsulfonyl, p-toluenesulfonyl (Tos), 4-nitrobenzenesulfonyl (NOSyl), 2-nitrobenzenesulfonyl, p-bromobenzenesulfonyl (Brosyl), trifluoroacetyl, acetyl or benzoyl; and the values of the other variables are as defined in the first, fourth, seventh, eleventh and / or twelfth embodiment of the second aspect.
[0253] In a fifteenth embodiment of the second aspect, the compound is represented by Formula IIFa:
[0254]
[0255] or a salt thereof.
[0256] Examples
[0257] All references provided in the examples are incorporated herein by reference. As used herein, all abbreviations, symbols and conventions are consistent with those used in contemporary scientific literature. See, for example, Janet S. Dodd (ed.), The ACS Style Guide: A Manual for Authors and Editors, 2nd edition, Washington, DC: American Chemical Society, 1997, the entire contents of which are incorporated herein by reference.
[0258] Example 1.
[0259] Synthesis of 8-(2-fluorobenzyl)imidazo[1,2-a]pyrazine-6-carbonitrile (nitrile)
[0260]
[0261] The title compound was synthesized in two steps according to patent literature procedure (WO2015 / 187470A1) as a yellow solid (0.60 g, 39% yield over two steps). 1 H NMR (500 MHz, methanol-d4) δ (ppm) 9.09 (s, 1H), 8.14 (s, 1H), 7.91 (s, 1H), 7.35 (t, 1H), 7.28 (m, 1H), 7.10 (m, 2H), 4.60 (s, 2H).
[0262] Synthesis of tert-butyl 2-((8-(2-fluorobenzyl)imidazo[1,2-a]pyrazin-6-yl)(imino)methyl)hydrazine-1-carboxylate (BOC-guanylhydrazone)
[0263]
[0264] 1 mol (252.25 g) of nitrile compound was charged into a 2 L cylindrical reactor equipped with a mechanical stirrer, followed by anhydrous methanol (1.5 L). Stirred at 120 to 140 RPM to obtain an ochre granular suspension. A 5 mol% (100 mL 0.5 M solution) methanol solution of sodium methoxide was added to the suspension at room temperature. The reactor jacket temperature was set to 18 ° C and the mixture was stirred under nitrogen until HPLC indicated complete conversion to the intermediate methyl imide ester (LC-MS: 100A% MH +285). 1.03 eq (136 g) of tert-butyl carbazate was then added portionwise over 15 minutes. The temperature was lowered to 9.2 °C and acetic acid (0.1 eq, 5.7 mL) was slowly added via a syringe through a septum. The temperature of the reaction mixture was slowly raised from 11.2 °C to 17.2 °C, producing a clear, coffee brown solution. The reactor jacket temperature was raised to 18 °C and the stirring rate was increased to 165 RPM. After 1 hour, a very thick yellow suspension was formed (the temperature of the reaction mixture was at about 21 °C). Additional anhydrous MeOH (550 mL) was then added. After about 24 hours, LC-MS indicated complete conversion to BOC-guanylhydrazone (MH + 385) and no methyl imide ester could be detected by LC-MS. The suspension was cooled to 8°C to 10°C and 0.06 equivalents (60 mL) of 1M NaOH aqueous solution was added, followed by saturated NaCl aqueous solution (150 mL) and deionized water (200 mL). The resulting mixture was stirred for several hours, after which the pH was adjusted to 8 to 9 with 10% aqueous sodium carbonate solution. The resulting mixture was then diluted with water (250 mL) and filtered through a 2L medium porosity glass frit, washed with deionized water (3×300 mL), and suction dried on the filter for about 45 minutes. The wet cake was washed with n-heptane (4×200 mL) and suction dried on the filter for 1 hour, then dried in a vacuum drying oven at 40°C to constant weight. 358.86 g (93%) of the product was obtained as a light yellow powdery substance. Mp (DSC) 181°C. HPLC (RP) [240nm]: 99.8A%. MS: MH+ 385 (100%).
[0265] 1 H-NMR(D6-DMSO): δppm 1.47(s,9H),4.56(s,2H),6.34(s,2H),7.12(t,J=7.48Hz,1H),7.15-7.21(m,1H),7.25-7 .33(m,1H),7.42(t,J=7.63Hz,1H),7.82(s,1H),8.29(s,1H),9.00-9.09(m,1H),9.13(br s,1H).
[0266] 13 C-NMR(D6-DMSO): δppm 28.15,31.91,78.44,115.04,116.28,116.50,124.14,124.37,128.56,131.58,131.79,135.40,139.09,142.53,149.66,152.87,160.39.
[0267] Synthesis of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine (Compound IF).
[0268]
[0269] 50 mmol (19.22 g) of BOC-guanylhydrazone and 2.2 equivalents of DABCO (12.34 g) were charged into a 500 ml pear-shaped flask with a magnetic stirring bar. Isopropyl acetate (300 mL) was then added and the mixture was stirred at room temperature for 2 minutes under nitrogen to produce a white thin suspension. Trifluoroethyl 2,2,2-trifluoroacetate (TFAOTfe or CF3C(=O)OCH2CF3, 2.5 equivalents, 25 g) was added to the suspension and the suspension was stirred at room temperature under nitrogen until HPLC and LC-MS showed complete conversion of the starting material. The resulting suspension was washed sequentially with saturated aqueous sodium bicarbonate solution, saturated aqueous sodium chloride solution and distilled water. The organic phase was filtered through a shorter plug of silica gel / diatomaceous earth and concentrated to a small volume (about 50 to 70 mL) at a rotary evaporator (water bath temperature: 45 to 50°C). The warm suspension was immediately diluted with n-heptane (150 mL), stirred for 2 hours while slowly cooling to 20° C., and then stirred for another 2 hours to 5° C. and filtered. The wet cake was washed with n-heptane (2×50 mL) and dried in a vacuum drying oven to constant weight. 16.7 g (92%) of the product was obtained as a snow-white powder. Mp (DSC) 196° C. HPLC (RP) [240 nm]: 99.8A%. MS: MH+ 363 (100%).
[0270] 1 H-NMR(D6-DMSO): δppm 4.60(s,2H)7.05-7.11(m,1H)7.14-7.20(m,1H)7.22-7.29(m,1H)7.43(br t,J=7.63Hz,1H)7.84-7.87(m,1H)8.23-8.27(m,1H)9.44(d,J=1.83Hz,1H)15.43(br s,1H).
[0271] 13C-NMR(D6-DMSO): δppm 160.90,158.95,154.13,152.73,152.43,151.76,138.89,135.50,130.91,130.87,128.34,128.27,12 6.39,124.11,124.02,122.47,120.33,119.12,118.18,116.68,116.04,115.01,114.84,31.64,31.61.
[0272] 19 F-NMR (D6-DMSO): δ ppm -116.96, -63.93.
[0273] [1] All references cited in this article are expressly incorporated by reference in their entirety.
Claims
1. A method for preparing a 3-substituted 1,2,4-triazole compound or a salt thereof having the following formula IE: Including making a guanylhydrazone compound having the following formula IIE: or its salts with R 11 C(O)OH、R 11 C(O)X'、R 11 C(S)X'、R 11 C(O)OE'、R 11 C(O)SR' or R 11 C(O)OR" is reacted in the presence of a base, wherein the base is selected from: trialkylamine, phosphazene, 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), guanidine, 1,1,3,3-tetramethylguanidine, optionally substituted pyridine and 1,4-diazabicyclo[2.2.2]-octane (DABCO), When using R 11 C(O)OH, an activator is also present, the activator being selected from carbodiimide, uronium, phosphonium, 2-alkyl-1-alkylcarbonyl-1,2-dihydroquinoline, 2-alkoxy-1-alkoxycarbonyl-1,2-dihydroquinoline, ethyl cyanohydroxyiminoacetate and alkyl chloroformates, in: Y is C; Among them, each J B is a halogen group; n is 1; R 11 is C optionally and independently substituted with 0 to 3 halo 1-6 alkyl; X' is a halogen; OE' is an activated ester leaving group selected from -O-(C 1-6 Alkyl), -O-(C 1-6 wherein the phenyl, heteroaryl and heterocyclyl are optionally substituted with 1 to 6 groups independently selected from halo, cyano, nitro, oxo, SO 3 H and SO 3 C 1-6 Alkyl radical substitution; SR' is a thioester leaving group selected from -S-(aryl), -S-(C 1-20 -S-(alkyl) and -S-(heteroaryl); R" is C(O)R 11 、C(O)R 11a 、N=CR 11b R 11c 、P(O)(OH) 2 or PH(O)OH; R 11a C 1-6 alkyl; R 11b and R 11c Each independently is C 1-6 Alkyl or phenyl, or R 11b and R 11c Together with the carbon atom to which it is attached, it forms C 4-6 Cycloalkyl; and G 1 is a guanylhydrazone protecting group selected from tert-butyloxycarbonyl (Boc), 2,2,2-trichloroethoxycarbonyl (Troc), benzyloxycarbonyl (Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), methylsulfonyl, p-toluenesulfonyl (Tos), 4-nitrobenzenesulfonyl (NOSyl), 2-nitrobenzenesulfonyl, p-bromobenzenesulfonyl (Brosyl), trifluoroacetyl, acetyl and benzoyl.
2. The method of claim 1, wherein the 3-substituted 1,2,4-triazole compound has the following formula IF: or a salt thereof, The guanylhydrazone compound has the following formula IIF: or a salt thereof.
3. The method of claim 1, wherein R 11 For CF 3 .
4. The method of claim 1, wherein the method comprises reacting the guanylhydrazone with R 11 C(O)OE' reaction.
5. The method of claim 4, wherein -OE' is -O-(C 1-6 haloalkyl).
6. The method of claim 4, wherein -OE' is -O-(CH 2 CF 3 ), -O-(nitrophenyl), -O-(dinitrophenyl), -O-(trichlorophenyl), -O-(pentafluorophenyl), -O-(sulfo-tetrafluorophenyl), -O-(succinimidyl), -O-(benzotriazole), -O-(7-azabenzotriazole), -O-(phthalimido), -O-(5-norbornene-endo-2,3-dicarboximide) or -O-(sulfo-succinimidyl).
7. The method of claim 1, wherein the method comprises reacting the guanylhydrazone with R 11 C(O)OR" reaction, where R" is N=CR 11b R 11c 、P(O)(OH) 2 or PH(O)OH.
8. The method of claim 1, wherein the method comprises reacting the guanylhydrazone with R in the presence of an activator. 11 C(O)OH reaction.
9. The method of claim 1, wherein the method comprises reacting the guanylhydrazone with R 11 C(O)SR' reaction.
10. The method of claim 9, wherein -SR' is -S-(ethyl), -S-(dodecyl), -S-(p-chlorophenyl) or -S-(2-benzothiazolyl).
11. The method of claim 1, wherein the base is 4-dimethylaminopyridine (DMAP).
12. The process of claim 1, wherein the base is DABCO.
13. The method according to any one of claims 1 to 12, wherein the method further comprises, after the reaction of the guanylhydrazone compound with the carboxylic acid, acyl halide, thioacyl halide, activated ester, thioester or acid anhydride, optionally deprotecting the guanylhydrazone protecting group by reacting the reaction product with a guanylhydrazone deprotecting agent.
14. The method of claim 1, wherein the 3-substituted 1,2,4-triazole compound is represented by the following formula IF: or its salts; and The method comprises reacting a guanylhydrazone of the following formula IIFa in the presence of a base: or its salts with CF 3 C(O)OCH 2 CF 3 reaction.
15. The process of claim 14, wherein the base is DABCO.
16. The method of claim 14, wherein the method further comprises purifying the 3-substituted 1,2,4-triazole compound of Formula IF by crystallization.
17. The method of claim 16, wherein the crystallization is carried out by reacting the guanylhydrazone compound of formula IIFa with CF 3 C(O)OCH 2 CF 3 After the reaction is complete, n-heptane is added to the reaction mixture.
18. The method according to any one of claims 15 to 17, wherein the guanylhydrazone compound of formula IIFa or a salt thereof is prepared by a method comprising the following steps: reacting a compound of formula IIIFa in a reaction solvent: First react with the second base, then with H 2 NNHC(O)OC(CH 3 ) 3 reaction.
19. The method of claim 18, wherein the reaction solvent is an alcohol.
20. The method of claim 19, wherein the reaction solvent is MeOH.
21. The method of claim 18, wherein the second base is NaOMe.
22. The compound represented by formula IIE: or a salt thereof, wherein Y is C; Among them, each J B is a halogen group; n is 1; and G 1 is a guanylhydrazone protecting group selected from the group consisting of tert-butyloxycarbonyl (Boc), 2,2,2-trichloroethoxycarbonyl (Troc), benzyloxycarbonyl (Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), methylsulfonyl, p-toluenesulfonyl (Tos), 4-nitrobenzenesulfonyl (NOSyl), 2-nitrobenzenesulfonyl, p-bromobenzenesulfonyl (Brosyl), acetyl and benzoyl.
23. The compound of claim 22, wherein the compound has the following formula IIF: or a salt thereof.
24. The compound of claim 22, wherein the compound is represented by the following formula IIFa: or a salt thereof.
